The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Alastair.Maxwell@glasgow.ac.uk
Molecular Cell & Systems Biology, Lab 422, Davidson Building
Dawson, J., Baine-Savanhu, F. K., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2022) A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry. Human Genetics and Genomics Advances, 3(4), 100130. (doi: 10.1016/j.xhgg.2022.100130) (PMID:35935919) (PMCID:PMC9352962)
McAllister, B. et al. (2022) Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 25(4), pp. 446-457. (doi: 10.1038/s41593-022-01033-5) (PMID:35379994)
Lu, A. T. et al. (2020) DNA methylation study of Huntington's disease and motor progression in patients and in animal models. Nature Communications, 11, 4529. (doi: 10.1038/s41467-020-18255-5) (PMID:32913184) (PMCID:PMC7484780)
Ellis, N. et al. (2020) Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s Disease. Biological Psychiatry, 87(9), pp. 857-865. (doi: 10.1016/j.biopsych.2019.12.010) (PMID:32087949)
Ciosi, M. et al. (2019) A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine, 48, pp. 568-580. (doi: 10.1016/j.ebiom.2019.09.020) (PMID:31607598) (PMCID:PMC6838430)
Lee, J.-M. et al. (2019) CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell, 178(4), 887-900.e14. (doi: 10.1016/j.cell.2019.06.036)
Ciosi, M. et al. (2018) Glutamine Codon Usage and Somatic Mosaicism of the HTT CAG Repeat Are Modifiers of Huntington Disease Severity. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.
Levesley, J., Baine, F., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2018) A CIS-acting Modifier of Age at Diagnosis of Huntington Disease in Black South African Patients. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.
Monckton, D. , Ciosi, M. , Mubarak, A., Cumming, S., Hamilton, G., Maxwell, A. , The International-Venezuela Collaborative Research Group, -, The Scottish Myotonic Dystrophy Genetic Variation Consortium, - and The Track-On HD Research Team, - (2016) Cryptic Polyglutamine Repeat Sequence Variation and Somatic Instability in Huntington’s Disease: Drivers of Pathology? European Huntington's Disease Network 9th Plenary Meeting, The Hague, The Netherlands, 16-18 Sep 2016. (doi: 10.1136/jnnp-2016-314597.2)
Dawson, J., Baine-Savanhu, F. K., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2022) A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry. Human Genetics and Genomics Advances, 3(4), 100130. (doi: 10.1016/j.xhgg.2022.100130) (PMID:35935919) (PMCID:PMC9352962)
McAllister, B. et al. (2022) Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience, 25(4), pp. 446-457. (doi: 10.1038/s41593-022-01033-5) (PMID:35379994)
Lu, A. T. et al. (2020) DNA methylation study of Huntington's disease and motor progression in patients and in animal models. Nature Communications, 11, 4529. (doi: 10.1038/s41467-020-18255-5) (PMID:32913184) (PMCID:PMC7484780)
Ellis, N. et al. (2020) Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s Disease. Biological Psychiatry, 87(9), pp. 857-865. (doi: 10.1016/j.biopsych.2019.12.010) (PMID:32087949)
Ciosi, M. et al. (2019) A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine, 48, pp. 568-580. (doi: 10.1016/j.ebiom.2019.09.020) (PMID:31607598) (PMCID:PMC6838430)
Lee, J.-M. et al. (2019) CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell, 178(4), 887-900.e14. (doi: 10.1016/j.cell.2019.06.036)
Ciosi, M. et al. (2018) Glutamine Codon Usage and Somatic Mosaicism of the HTT CAG Repeat Are Modifiers of Huntington Disease Severity. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.
Levesley, J., Baine, F., Ciosi, M. , Maxwell, A. , Monckton, D. G. and Krause, A. (2018) A CIS-acting Modifier of Age at Diagnosis of Huntington Disease in Black South African Patients. EHDN 2018 Plenary Meeting, Vienna, Austria, 14-16 Sep 2018.
Monckton, D. , Ciosi, M. , Mubarak, A., Cumming, S., Hamilton, G., Maxwell, A. , The International-Venezuela Collaborative Research Group, -, The Scottish Myotonic Dystrophy Genetic Variation Consortium, - and The Track-On HD Research Team, - (2016) Cryptic Polyglutamine Repeat Sequence Variation and Somatic Instability in Huntington’s Disease: Drivers of Pathology? European Huntington's Disease Network 9th Plenary Meeting, The Hague, The Netherlands, 16-18 Sep 2016. (doi: 10.1136/jnnp-2016-314597.2)
https://orcid.org/0000-0002-2414-2252